The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients
Abstract
The prevalence of left ventricular hypertrophy (LVH) rises with severity of hypertension (HT), age, and obesity. Its prevalence ranges from 20% in mildly hypertensive patients to almost 100% in those with severe or complicated HT. However, the diagnosis of LVH is not straightforward, and the definitions and criteria used in clinical studies lack consistency. While many factors play a role in the onset and progression of LVH, blood pressure (BP) is recognized as a central factor. Twenty-four-hour BP measurements are more closely related to LVH than conventional BP readings taken in the clinician's office. Increased renin-angiotensin system (RAS) activity also plays an important role in the development of LVH, and various studies show a correlation between plasma renin activity and left ventricular mass (LVM). LVH is a recognized marker of HT-related target organ damage, and a strong and independent risk factor for adverse cardiovascular (CV) outcomes. CV risk increases with increasing LVM, and decreases with regression of LVH in response to antihypertensive treatment. Therefore the detection, prevention, and reversal of LVH are important goals in HT management. Most antihypertensive drugs can attenuate BP and LVH. However, each drug class may induce LVH regression to a different extent and these extents seldom correlate with the degree of BP reduction achieved. Data from the few large comparative studies in this area suggest that certain classes of antihypertensive drugs and/or their combinations are more effective than others. In particular, calcium channel blockers and drugs that target the RAS, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), appear to have a specific effect on LVH, independent of BP reduction. Guidelines, therefore, have recommended these drug classes for the treatment of hypertensive patients with LVH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D., & Laragh, J. H. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-5-345 · Cited by 2,366
Sokolow, M., & Lyon, T. P. (1949) · American Heart Journal · doi:10.1016/0002-8703(49)90562-1 · Cited by 1,980
The CAFE Investigators, CAFE Steering Committee and Writing Committee, Williams, B., Lacy, P. S., Thom, S. M., Cruickshank, K., Stanton, A., Collier, D., Hughes, A. D., Thurston, H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.595496 · Cited by 1,645
Parati, G., Pomidossi, G., Albini, F., Malaspina, D., & Mancia, G. (1987) · Journal of Hypertension · doi:10.1097/00004872-198702000-00013 · Cited by 952
Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension
Devereux, R. B. (2004) · JAMA · doi:10.1001/jama.292.19.2350 · Cited by 881
A point-score system for the ECG diagnosis of left ventricular hypertrophy
Romhilt, D. W., & Estes, E. H. (1968) · American Heart Journal · doi:10.1016/0002-8703(68)90035-5 · Cited by 856
LEVY, D., ANDERSON, K. M., SAVAGE, D. D., KANNEL, W. B., CHRISTIANSEN, J. C., & CASTELLI, W. P. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-1-7 · Cited by 812
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
Klingbeil, A. U., Schneider, M., Martus, P., Messerli, F. H., & Schmieder, R. E. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00158-x · Cited by 761
Self-citation
Cited by
Brandt, M. C., Mahfoud, F., Reda, S., Schirmer, S. H., Erdmann, E., Böhm, M., & Hoppe, U. C. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.034 · Cited by 501
Cuspidi, C., Sala, C., Negri, F., Mancia, G., Morganti, A., & on behalf of the Italian Society of Hypertension (2012) · Journal of Human Hypertension · doi:10.1038/jhh.2011.104 · Cited by 333
Savelieva, I., Kakouros, N., Kourliouros, A., & Camm, A. J. (2011) · Europace · doi:10.1093/europace/eur002 · Cited by 312
Influence of Physical Activity on Hypertension and Cardiac Structure and Function
Hegde, S. M., & Solomon, S. D. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0588-3 · Cited by 272
Optimal critical mass in the two dimensional Keller–Segel model in R 2
Dolbeault, J., & Perthame, B. (2004) · Comptes Rendus. Mathématique · doi:10.1016/j.crma.2004.08.011 · Cited by 262
Metadata
- Authors
- Ruilope, L. M., & Schmieder, R. E.
- Venue
- American Journal of Hypertension
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-05-01
- Volume
- 21
- Issue
- 5
- Pages
- 500-508
- ISSN
- 0895-7061 (ISSN-L)
- 1941-7225
- OpenAlex
- W2034336585
- Cited by
- 258
- References
- 70
- FWCI
- 13.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients. https://app.cochat.ai/papers/10.1038/ajh.2008.16
- The paper
- Ruilope, L. M., & Schmieder, R. E. (2008). Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients. American Journal of Hypertension. https://doi.org/10.1038/ajh.2008.16
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.